Cargando…
Case report: POLE (P286R) mutation in a case of recurrent intestinal leakage and its treatment
In recent years, although new drugs and molecular markers have been used to treat metastatic colorectal cancer, there has been little progress in the immunotherapy of advanced colon cancer. The development of sequencing and multiomics technology helps us classify patients more accurately, and then f...
Autores principales: | Xiang, Dang, Fu, Gongbo, Chen, Yitian, Chu, Xiaoyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061108/ https://www.ncbi.nlm.nih.gov/pubmed/37007102 http://dx.doi.org/10.3389/fonc.2023.1028179 |
Ejemplares similares
-
The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy
por: Ahn, Sung-Min, et al.
Publicado: (2016) -
P286 Histoplasmosis in Sri Lanka
por: Sigera, Liyanage Shamithra Madhumali, et al.
Publicado: (2022) -
Risk of Second Primary Malignancies Based on the Histological Subtypes of Colorectal Cancer
por: Wu, Meijuan, et al.
Publicado: (2021) -
Stem-cell therapy via gastroscopy improves the outcome of esophageal anastomotic leakage
por: Hu, Yannan, et al.
Publicado: (2022) -
Primary upper pole liposarcoma of the kidney with invasion to inferior vena cava: A case report
por: Parizi, Mehdi Kardoust, et al.
Publicado: (2019)